全球新生兒篩檢市場

全球新生兒篩檢市場預計到2030年將達到19億美元。

2024年全球新生兒篩檢市場規模估計為13億美元，預計2030年將達到19億美元，在分析期間（2024-2030年）內複合年成長率（CAGR）為7.2%。本報告分析的細分市場之一－新生兒篩檢耗材，預計複合年成長率為7.5%，到分析期末將達到14億美元。新生兒篩檢設備細分市場預計在分析期間內複合年成長率為6.3%。

美國市場規模估計為3.306億美元，而中國市場預計將以10.6%的複合年成長率成長。

據估計，2024年美國新生兒篩檢市場規模將達3.306億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到4.672億美元，在2024年至2030年的分析期內，複合年成長率（CAGR）將達到10.6%。其他值得關注的區域市場分析包括日本和加拿大，預計在分析期間內，兩國的複合年成長率分別為3.6%和6.4%。在歐洲，德國的複合年成長率預計約為4.2%。

全球新生兒篩檢市場—主要市場趨勢與促進因素概述

什麼是新生兒篩檢？為什麼它很重要？

新生兒篩檢是一項重要的公共衛生項目，旨在對新生兒進行出生後立即篩檢，以發現某些遺傳、代謝和發育障礙。這些篩檢對於及早發現疾病至關重要，因為這些疾病若不及時治療，可能導致嚴重的健康問題，包括發育遲緩、身體殘疾甚至死亡。透過新生兒篩檢早期發現疾病，可以採取適當的干涉措施，例如藥物治療、飲食調整和手術，從而預防長期併發症，提高兒童的生活品質。

新生兒篩檢計畫通常包括多種疾病的檢測，例如甲狀腺機能低下症（PKU）、先天性甲狀腺功能低下症、鐮狀細胞疾病和囊腫纖維化。技術的不斷進步正在擴大可檢測疾病的範圍，使新生兒篩檢成為現代醫學中不可或缺的工具。透過早期發現這些疾病，新生兒篩檢計畫有助於降低嬰兒死亡率，並改善整體公共衛生狀況。

新生兒篩檢市場正在如何發展？

新生兒篩檢市場正受益於技術進步和篩檢項目範圍的不斷擴大而迅速發展。其中，串聯式質譜質譜（MS/MS）技術的日益普及是推動市場發展的關鍵趨勢之一。這項技術透過對單份血液樣本進行檢測，即可檢測多種代謝性疾病，從而實現更快、更準確、更全面的檢測，徹底革新了新生兒篩檢。此外，包括次世代定序（NGS）在內的基因篩檢技術也正被整合到新生兒篩檢計畫中，從而能夠檢測出更廣泛的遺傳性疾病，包括罕見疾病。

另一個重要趨勢是新生兒篩檢中就地檢驗（POC​​T）的普及。 POCT設備便攜，可在床邊即時檢測並獲得結果，從而縮短確診疾病的治療啟動時間。數位健康平台的擴展也推動了市場發展，簡化了數據收集、分析和報告流程，提高了新生兒篩檢的效率。這種發展使得更多嬰兒能夠更快篩檢，尤其是在醫療基礎設施匱乏的地區。

哪些疾病正在推動新生兒篩檢的需求？

多種疾病推動了新生兒篩檢的需求，其中苯酮尿症 (PKU) 和先天性甲狀腺機能低下症代謝性疾病是最常見的篩檢項目。如果這些疾病未能早期發現，可能導致嚴重的發育障礙，但透過適當的干涉，其影響可以顯著降低。囊腫纖維化和鐮狀細胞疾病等遺傳性疾病也是推動篩檢需求的主要因素，因為早期治療可以預防嚴重的併發症，並改善長期健康。

此外，溶小體儲積症（LSDs）是一組罕見的遺傳性疾病，正日益納入新生兒篩檢計畫。診斷技術的進步使得更多罕見疾病得以檢測，早期治療可以改善患兒的預後。需要早期飲食干預的遺傳性代謝紊亂病例的增加，也促使全球對新生兒篩檢計畫的需求不斷成長。

新生兒篩檢市場的主要成長要素是什麼？

新生兒篩檢市場的成長受多種因素驅動，其中包括遺傳性和代謝性疾病盛行率的不斷上升，這些疾病需要早期診斷和介入。政府旨在擴大新生兒篩檢計畫的強制規定和政策是關鍵促進因素，確保了常規檢測涵蓋的疾病種類不斷增加。技術進步，特別是質譜和基因定序技術的進步，也透過實現更全面、更準確的篩檢，推動了市場成長。

另一個重要因素是醫護人員和家長日益認知到早期檢測對於預防長期健康併發症的重要性。醫療基礎設施的改善，尤其是在發展中地區，正在擴大新生兒篩檢的覆蓋範圍，從而促進市場成長。此外，公共衛生機構與私人公司之間合作的加強，也有助於先進篩檢技術的應用，進而改善患者的治療效果。

部分：

產品類型（耗材、設備）、檢測類型（乾血斑檢測、聽力篩檢檢測、嚴重心臟疾病（CCHD）篩檢檢測）、技術（免疫檢測/酵素檢測法、串聯式質譜質譜法、檢測法、聽力篩檢技術、脈搏血氧計、其他技術）

受訪公司範例

• AB Sciex LLC
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• GE Healthcare
• Masimo Corporation
• Medtronic PLC
• Natus Medical, Inc.
• PerkinElmer, Inc.
• Trivitron Healthcare
• Waters Corporation

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具，改變您分析市場和競爭情報的方式。

Market Glass, Inc. 並沒有採用典型的 LLM 或產業專用的SLM 方法，而是建立了一個由世界各地領域專家精心策劃的內容庫，其中包括影片轉錄、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

在最新發布的報告中，Market Glass, Inc. 將關稅對地理市場的影響納入考量，並根據公司總部所在地、製造地以及進出口（成品和OEM產品）情況，預測企業競爭地位的變化。這種複雜多變的市場現實將對競爭對手產生許多影響，包括銷貨成本增加、盈利下降以及供應鏈重組。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章 市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲
• 亞太地區
• 澳洲
• 印度
• 韓國
• 亞太其他地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 競賽

Global Newborn Screening Market to Reach US$1.9 Billion by 2030

The global market for Newborn Screening estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Newborn Screening Consumables, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Newborn Screening Instruments segment is estimated at 6.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$330.6 Million While China is Forecast to Grow at 10.6% CAGR

The Newborn Screening market in the U.S. is estimated at US$330.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$467.2 Million by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Newborn Screening Market - Key Trends & Drivers Summarized

What Is Newborn Screening and Why Is It Essential?

Newborn screening is a vital public health program that tests infants for certain genetic, metabolic, and developmental disorders shortly after birth. These screenings are essential for detecting conditions that, if left untreated, can lead to severe health problems, including developmental delays, physical disabilities, and even death. Early detection through newborn screening allows for timely interventions, such as medications, dietary changes, or surgeries, which can prevent long-term complications and improve the child’s quality of life.

Newborn screening programs typically include tests for a variety of conditions, such as phenylketonuria (PKU), congenital hypothyroidism, sickle cell disease, cystic fibrosis, and more. With the continuous advancement in technology, the range of detectable disorders is expanding, making newborn screening an indispensable tool in modern healthcare. By identifying these conditions early, newborn screening programs contribute to reducing infant mortality and improving overall public health outcomes.

How Is the Newborn Screening Market Evolving?

The newborn screening market is evolving rapidly, driven by technological advancements and the expansion of screening panels. One of the key trends shaping the market is the increasing use of tandem mass spectrometry (MS/MS), a technology that allows for the detection of multiple metabolic disorders from a single blood sample. This technology has revolutionized newborn screening by enabling faster, more accurate, and comprehensive testing. Additionally, genetic screening techniques, including next-generation sequencing (NGS), are being integrated into newborn screening programs, allowing for the detection of a broader range of genetic conditions, including rare diseases.

Another significant trend is the shift towards point-of-care testing (POCT) for newborn screening. POCT devices are portable and enable immediate testing and results at the bedside, reducing the time it takes to begin treatment for diagnosed conditions. The expansion of digital healthcare platforms is also playing a role in the evolution of the market by streamlining data collection, analysis, and reporting processes, leading to more efficient newborn screening workflows. This evolution is allowing more infants to be screened faster, particularly in regions where access to healthcare infrastructure may be limited.

Which Conditions Are Driving the Demand for Newborn Screening?

Several conditions are driving the demand for newborn screening, with metabolic disorders such as phenylketonuria (PKU) and congenital hypothyroidism being among the most commonly screened. These conditions can cause serious developmental issues if not detected early, but with appropriate interventions, their impacts can be significantly mitigated. Genetic disorders, such as cystic fibrosis and sickle cell disease, are also major drivers of screening demand, as early treatment can prevent severe complications and improve long-term health outcomes.

Additionally, lysosomal storage disorders (LSDs), which are a group of rare genetic conditions, are increasingly being included in newborn screening panels. As diagnostic technologies improve, more rare diseases are being detected, leading to early treatments that can improve the prognosis for affected children. The rise of inherited metabolic disorders, which require early dietary interventions, is also contributing to the growing demand for newborn screening programs across the globe.

What Are the Key Growth Drivers in the Newborn Screening Market?

The growth in the newborn screening market is driven by several factors, including the increasing prevalence of genetic and metabolic disorders, which necessitate early diagnosis and intervention. Government mandates and initiatives focused on expanding newborn screening programs are a key driver, as they ensure that a growing number of conditions are included in routine testing. Technological advancements, particularly in mass spectrometry and genetic sequencing, are also propelling market growth by enabling more comprehensive and accurate screening.

Another important factor is the rising awareness among healthcare providers and parents about the importance of early detection in preventing long-term health complications. As healthcare infrastructure improves, especially in developing regions, access to newborn screening is expanding, contributing to market growth. Additionally, collaborations between public health organizations and private companies are increasing, leading to more widespread adoption of advanced screening technologies and better patient outcomes.

SCOPE OF STUDY:

The report analyzes the Newborn Screening market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Consumables, Instruments); Test Type (Dry Blood Spot Tests, Hearing Screening Tests, Critical Congenital Heart Disease (CCHD) Screening Tests); Technology (Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry, Other Technologies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 11 Featured) -

• AB Sciex LLC
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• GE Healthcare
• Masimo Corporation
• Medtronic PLC
• Natus Medical, Inc.
• PerkinElmer, Inc.
• Trivitron Healthcare
• Waters Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Global Economic Update
  • Newborn Screening - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Awareness of Early Detection and Prevention Drives Growth in Newborn Screening Programs Globally
  • Increasing Adoption of Genetic and Metabolic Screening Expands Opportunities for Early Diagnosis of Congenital Disorders
  • Technological Advancements in Mass Spectrometry Propel Growth in Newborn Screening for Rare Metabolic Disorders
  • Growing Focus on Early Detection of Cystic Fibrosis and Sickle Cell Disease Strengthens Demand for Newborn Screening
  • Expansion of Government-Funded Newborn Screening Programs Drives Adoption in Public Health Systems Worldwide
  • Increasing Use of Tandem Mass Spectrometry (MS/MS) in Newborn Screening Expands Precision Diagnosis Capabilities
  • Rising Adoption of DNA-Based Screening Technologies for Inherited Disorders Strengthens Market for Genomic Newborn Testing
  • Growing Demand for Point-of-Care Newborn Screening Expands Access to Early Detection in Remote and Low-Income Regions
  • Emerging Focus on Screening for Lysosomal Storage Disorders Propels Innovation in Newborn Screening Assays
  • Increasing Use of Digital Data Management Systems in Newborn Screening Programs Drives Demand for Integrated Solutions
  • Rising Demand for Expanded Newborn Screening for Immunodeficiencies and Endocrine Disorders Expands Addressable Market
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Newborn Screening Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Newborn Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Dry Blood Spot Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Dry Blood Spot Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Dry Blood Spot Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hearing Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hearing Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Hearing Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Immunoassays & Enzymatic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Immunoassays & Enzymatic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Immunoassays & Enzymatic Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Tandem Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Molecular Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Molecular Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Molecular Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hearing Screening Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hearing Screening Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Hearing Screening Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Pulse Oximetry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Pulse Oximetry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Pulse Oximetry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• JAPAN
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• CHINA
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• EUROPE
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Newborn Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• FRANCE
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• GERMANY
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Newborn Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• INDIA
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Newborn Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Newborn Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• AFRICA
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030

IV. COMPETITION